Transcript: Abbott Laboratories Q1 2026 Earnings Conference Call - Abbott Laboratories (NYSE:ABT)

Transcript: Abbott Laboratories Q1 2026 Earnings Conference Call - Abbott Laboratories (NYSE:ABT)

Abbott: Q1 Earnings Snapshot

ABBOTT PARK, Ill. (AP) — ABBOTT PARK, Ill. (AP) — Abbott Laboratories (ABT) on Thursday reported first-quarter earnings of $1.08 billion.

Earnings Snapshot: Abbott Laboratories tops Q1 revenue estimates; lowers FY26 Adj. profit

Earnings Snapshot: Abbott Laboratories tops Q1 revenue estimates; lowers FY26 Adj. profit outlook

Abbott lowers earnings forecast after $21B Exact Sciences buy

CEO Robert Ford said the companies are a good cultural fit and he expects demand for Exact’s colon cancer screening test to increase.

Abbott cuts profit forecast in wake of cancer-screening deal

It still projects full-year 2026 comparable sales growth of 6.5% to 7.5%

Abbott Laboratories (ABT) Stock Falls 4.3% After Q1 Earnings Despite Revenue Beat

Key Takeaways Abbott shares plunge 4.34% even as revenue surpasses forecasts and earnings hold steady Operating margins compress significantly as expenses outpace revenue expansion Company slashes annual earnings forecast, sparking investor concerns Exact Sciences acquisition strengthens oncology portfolio while pressuring near-term profits First-quarter results exceed expectations, yet margin weakness drives stock decline Shares of Abbott Labo…